Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial.
Does the changing sex ratio of multiple sclerosis give opportunities for intervention?
[Argyrophil fibrils in the foci of multiple sclerosis; tissue in the central nervous parenchyma].
Epidemiology and genetic aspects of multiple sclerosis in India.
Relapsing Remitting Multiple Sclerosis in an Iranian Patient with Neurofibromatosis Type I.
Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.
Neuregulin/ErbB Signaling in Developmental Myelin Formation and Nerve Repair.
Radiolabeled anti-aquaporin-4 protein antibody imaging: a valuable method for determining neuromyelitis optica.
Systematic analysis of transcription-level effects of neurodegenerative diseases on human brain metabolism by a newly reconstructed brain-specific metabolic network.
Cognitive dysfunction in pediatric multiple sclerosis.
Palmoplantar Keratoderma and Charcot-Marie-Tooth: combination of two independent genetic diseases? Identification of two point mutations in CMT2 and PPK genes by whole exome sequencing.
[Need for creating Polish registry of multiple sclerosis patients].
Let's rehabilitate cognitive rehabilitation in multiple sclerosis.
Kalopanaxsaponin A Exerts Anti-Inflammatory Effects in Lipopolysaccharide-Stimulated Microglia via Inhibition of JNK and NF-κB/AP-1 Pathways.
Human polyoma JC virus minor capsid proteins, VP2 and VP3, enhance large T antigen binding to the origin of viral DNA replication: Evidence for their involvement in regulation of the viral DNA replication.
Prevalence and Incidence of Multiple Sclerosis in Fars Province, Southern Iran.
Epidemiology and Current Treatment of Neuromyelitis Optica: A Systematic Review.
Marine Diterpenoids as Potential Anti-Inflammatory Agents.
LOTUS, a possible endogenous inhibitor of axonal degeneration, as a new biomarker for multiple sclerosis.
Estimating a Preference-Based Index for an Eight-Dimensional Health State Classification System for Multiple Sclerosis.
Editorial: Fatigue in Multiple Sclerosis.
Alemtuzumab and Multiple Sclerosis: Another Note of Caution.
Neuromyelitis optica: Contribution of therapeutic responses markers monitoring in patients given rituximab.
Tysabri® (natalizumab) data at ECTRIMS reaffirm positive effects of treatment for people with relapsing forms of MS
Assessment of the effect of cigarette smoking on regional brain volumes and lesion load in patients with clinically isolated syndrome.

Pages